Content Team, Author at Xeltis

Exceptional 6-month data from Xeltis’ FIH aXess vascular conduit trial published in Journal of Vascular Access

The exceptional six-month data from Xeltis’ first-in-human (FIH) aXess conduit trial has been published in the Journal of Vascular Access....

Content Team In Clinical Trials, Events, Latest News

Outstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial presented at VEITHsymposium 2023

aXess demonstrated exceptional patency rates and no infections to date Xeltis, a leading developer of transformative implants that enable the...

Content Team In Latest News

Xeltis appoints Luciën van Os as Chief Operating Officer

Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, today announces the...

Content Team In Latest News

Xeltis secures additional €12.5 million from European Innovation Council Fund in final close of D2 financing

Funding extends Xeltis’ Series D2 financing round to €44.5 million. Xeltis a leading developer of transformative implants that enable the...

Content Team In Latest News

XABG unprecedented preclinical outcomes for a CABG device may outperform saphenous veins

Preclinical data on Xeltis restorative Coronary Artery Bypass Graft (CABG) device, XABG, show unprecedented one-year patency for a CABG device,...

Content Team In Clinical Trials

Xeltis’ aXess implanted in first patient in Poland

Xeltis’ restorative vascular access graft, aXess, has been successfully implanted in the first patient in Poland, as part of the...

Content Team In Clinical Trials

Xeltis’ aXess implanted in first patient in Greece

aXess, Xeltis’ restorative vascular access graft for hemodialysis, has been successfully implanted in the first patient in Greece, as part...

Content Team In Latest News, Press Releases

Xeltis presents excellent six-month first-in-human data from aXess hemodialysis vascular graft trial at Vascular Access Society Congress

aXess graft demonstrated excellent patency, low rates of infection and re-intervention Data indicates a significant improvement in performance compared to...

Content Team In Finances

Xeltis raises €32 million to drive clinical development of world’s most advanced restorative cardiovascular devices

New investors DaVita Venture Group and Invest-NL join syndicate of international investors, including Grand Pharma and EQT Life Sciences, investing...

Content Team In Clinical Trials

Xeltis materials confirm outstanding restorative properties

The Xeltis materials have been showing outstanding restorative outcomes in preclinical trials presented by Dr Madeline Cramer, University of Pittsburgh,...

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent	1 year	CookieYes sets this cookie to record the default button state of the corresponding category and the status of CCPA. It works only in coordination with the primary cookie.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Cookie	Duration	Description
_ga	1 year 1 month 4 days	Google Analytics sets this cookie to calculate visitor, session and campaign data and track site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognise unique visitors.
_ga_*	1 year 1 month 4 days	Google Analytics sets this cookie to store and count page views.